To evaluate the functional impact of ERRα in prostate cancer growth, we generated both stable ERRα- overexpression and -knockdown transductants in two prostate cancer cell lines (including AR-positive: LNCaP; AR-negative: DU145) for in vitro and in vivo growth phenotype analyses (Figure 2 and Figure S2). This evidence concerns the gene ESRRA and prostate carcinoma.